The DOI matches its Crossref record; 311 of the 311 references it cites were found in a registry or an index.
Mechanisms driving the immunoregulatory function of cancer cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
DNA methylation and its basic function
Moore, L. D., Le, T., & Fan, G. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.112 · Cited by 4,906
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go
Tkach, M., & Théry, C. (2016) · Cell · doi:10.1016/j.cell.2016.01.043 · Cited by 3,444
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Anderson, N. M., & Simon, M. C. (2020) · Current Biology · doi:10.1016/j.cub.2020.06.081 · Cited by 2,718
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., Hoshino, A., Mark, M. T., Molina, H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3169 · Cited by 2,692
NF-κB, inflammation, immunity and cancer: coming of age
Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
Brabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.118 · Cited by 1,961
Landon, M., Saam, J., Brown, K. L., Moyes, K., Evans, B., & Wenstrup, R. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,939
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Cancer metabolism: looking forward
Martínez-Reyes, I., & Chandel, N. S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,824
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
A single-cell and spatially resolved atlas of human breast cancers
Wu, S. Z., Al-Eryani, G., Roden, D. L., Junankar, S., Harvey, K., Andersson, A., Thennavan, A., Wang, C., Torpy, J. R., Bartonicek, N., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00911-1 · Cited by 1,775
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757
Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology
Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V., & Madabhushi, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0252-y · Cited by 1,698
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621
Chromosomal instability drives metastasis through a cytosolic DNA response
Bakhoum, S. F., Ngo, B., Laughney, A. M., Cavallo, J.-A., Murphy, C. J., Ly, P., Shah, P., Sriram, R. K., Watkins, T. B. K., Taunk, N. K., et al. (2018) · Nature · doi:10.1038/nature25432 · Cited by 1,593
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
Immune checkpoint signaling and cancer immunotherapy
He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,371
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Kim, N., Kim, H. K., Lee, K., Hong, Y., Cho, J. H., Choi, J. W., Lee, J.-I., Suh, Y.-L., Ku, B. M., Eum, H. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16164-1 · Cited by 1,274
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
Watson, M. J., Vignali, P. D. A., Mullett, S. J., Overacre-Delgoffe, A. E., Peralta, R. M., Grebinoski, S., Menk, A. V., Rittenhouse, N. L., DePeaux, K., Whetstone, R. D., et al. (2021) · Nature · doi:10.1038/s41586-020-03045-2 · Cited by 1,259
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Radiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,070
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Klemm, F., Maas, R. R., Bowman, R. L., Kornete, M., Soukup, K., Nassiri, S., Brouland, J.-P., Iacobuzio-Donahue, C. A., Brennan, C., Tabar, V., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.007 · Cited by 1,037
Histone Modifications and Cancer
Audia, J. E., & Campbell, R. M. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019521 · Cited by 1,024
Cell-programmed nutrient partitioning in the tumour microenvironment
Reinfeld, B. I., Madden, M. Z., Wolf, M. M., Chytil, A., Bader, J. E., Patterson, A. R., Sugiura, A., Cohen, A. S., Ali, A., Do, B. T., et al. (2021) · Nature · doi:10.1038/s41586-021-03442-1 · Cited by 1,023
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science · doi:10.1126/science.aaz7015 · Cited by 966
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
Moynahan, M. E., & Jasin, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2851 · Cited by 930
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912
Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer.
Kieffer, Y., Hocine, H. R., Gentric, G., Pelon, F., Bernard, C., Bourachot, B., Lameiras, S., Albergante, L., Bonneau, C., Guyard, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1384 · Cited by 910
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893
Kumagai, S., Koyama, S., Itahashi, K., Tanegashima, T., Lin, Y.-T., Togashi, Y., Kamada, T., Irie, T., Okumura, G., Kono, H., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.001 · Cited by 892
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Wang, Z., Aguilar, E. G., Luna, J. I., Dunai, C., Khuat, L. T., Le, C. T., Mirsoian, A., Minnar, C. M., Stoffel, K. M., Sturgill, I. R., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0221-5 · Cited by 865
Unmasking senescence: context-dependent effects of SASP in cancer
Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863
Metabolic Interactions in the Tumor Microenvironment
Lyssiotis, C. A., & Kimmelman, A. C. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.003 · Cited by 853
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852
Contextual determinants of TGFβ action in development, immunity and cancer
David, C. J., & Massagué, J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0007-0 · Cited by 851
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
Sparmann, A., & Bar-Sagi, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.028 · Cited by 851
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Husain, Z., Huang, Y., Seth, P., & Sukhatme, V. P. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202702 · Cited by 822
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785
Zhang, Y., Chen, H., Mo, H., Hu, X., Gao, R., Zhao, Y., Liu, B., Niu, L., Sun, X., Yu, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.010 · Cited by 783
Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity
Ringel, A. E., Drijvers, J. M., Baker, G. J., Catozzi, A., García-Cañaveras, J. C., Gassaway, B. M., Miller, B. C., Juneja, V. R., Nguyen, T. H., Joshi, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.009 · Cited by 780
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767
Szabo, P. A., Levitin, H. M., Miron, M., Snyder, M. E., Senda, T., Yuan, J., Cheng, Y. L., Bush, E. C., Dogra, P., Thapa, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12464-3 · Cited by 756
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
Tran, D. Q., Ramsey, H., & Shevach, E. M. (2007) · Blood · doi:10.1182/blood-2007-06-094656 · Cited by 743
WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Janjigian, Y. Y., Kawazoe, A., Yañez, P., Li, N., Lonardi, S., Kolesnik, O., Barajas, O., Bai, Y., Shen, L., Tang, Y., et al. (2021) · Nature · doi:10.1038/s41586-021-04161-3 · Cited by 720
The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
Bakhoum, S. F., & Cantley, L. C. (2018) · Cell · doi:10.1016/j.cell.2018.08.027 · Cited by 717
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.117 · Cited by 665
Muhl, L., Genové, G., Leptidis, S., Liu, J., He, L., Mocci, G., Sun, Y., Gustafsson, S., Buyandelger, B., Chivukula, I. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17740-1 · Cited by 665
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì, A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. (2017) · Nature · doi:10.1038/nature24673 · Cited by 627
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Theodoraki, M.-N., Yerneni, S. S., Hoffmann, T. K., Gooding, W. E., & Whiteside, T. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2664 · Cited by 624
KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
Cascone, T., McKenzie, J. A., Mbofung, R. M., Punt, S., Wang, Z., Xu, C., Williams, L. J., Wang, Z., Bristow, C. A., Carugo, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.024 · Cited by 611
Eggert, T., Wolter, K., Ji, J., Ma, C., Yevsa, T., Klotz, S., Medina-Echeverz, J., Longerich, T., Forgues, M., Reisinger, F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.003 · Cited by 609
Morrissey, S. M., Zhang, F., Ding, C., Montoya-Durango, D. E., Hu, X., Yang, C., Wang, Z., Yuan, F., Fox, M., Zhang, H.-G., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.09.002 · Cited by 605
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
Self-citationCullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
Marcus, L., Fashoyin-Aje, L. A., Donoghue, M., Yuan, M., Rodriguez, L., Gallagher, P. S., Philip, R., Ghosh, S., Theoret, M. R., Beaver, J. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0327 · Cited by 578
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
Mereiter, S., Balmaña, M., Campos, D., Gomes, J., & Reis, C. A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.006 · Cited by 565
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Jung, H., Kim, H. S., Kim, J. Y., Sun, J.-M., Ahn, J. S., Ahn, M.-J., Park, K., Esteller, M., Lee, S.-H., & Choi, J. K. (2019) · Nature Communications · doi:10.1038/s41467-019-12159-9 · Cited by 529
Metabolic landscape of the tumor microenvironment at single cell resolution
Xiao, Z., Dai, Z., & Locasale, J. W. (2019) · Nature Communications · doi:10.1038/s41467-019-11738-0 · Cited by 524
Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma
Smyrk, T. C., Watson, P., Kaul, K., & Lynch, H. T. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2417::aid-cncr1276>3.0.co;2-u · Cited by 522
Gpr132 sensing of lactate mediates tumor–macrophage interplay to promote breast cancer metastasis
Chen, P., Zuo, H., Xiong, H., Kolar, M. J., Chu, Q., Saghatelian, A., Siegwart, D. J., & Wan, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614035114 · Cited by 520
Yang, Y., Li, C.-W., Chan, L.-C., Wei, Y., Hsu, J.-M., Xia, W., Cha, J.-H., Hou, J., Hsu, J. L., Sun, L., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0060-4 · Cited by 512
Co-option of Neutrophil Fates by Tissue Environments
Ballesteros, I., Rubio-Ponce, A., Genua, M., Lusito, E., Kwok, I., Fernández-Calvo, G., Khoyratty, T. E., van Grinsven, E., González-Hernández, S., Nicolás-Ávila, J. Á., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.003 · Cited by 504
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Wellenstein, M. D., Coffelt, S. B., Duits, D. E. M., van Miltenburg, M. H., Slagter, M., de Rink, I., Henneman, L., Kas, S. M., Prekovic, S., Hau, C.-S., et al. (2019) · Nature · doi:10.1038/s41586-019-1450-6 · Cited by 500
Self-citationRobert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Joseph, R. W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6270 · Cited by 482
Dolcetti, R., Viel, A., Doglioni, C., Russo, A., Guidoboni, M., Capozzi, E., Vecchiato, N., Macrì, E., Fornasarig, M., & Boiocchi, M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65436-3 · Cited by 480
Loi, S., Giobbie-Hurder, A., Gombos, A., Bachelot, T., Hui, R., Curigliano, G., Campone, M., Biganzoli, L., Bonnefoi, H., Jerusalem, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30812-x · Cited by 470
Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 466
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 465
Identification of bacteria-derived HLA-bound peptides in melanoma
Kalaora, S., Nagler, A., Nejman, D., Alon, M., Barbolin, C., Barnea, E., Ketelaars, S. L. C., Cheng, K., Vervier, K., Shental, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03368-8 · Cited by 457
Evolution of Metastases in Space and Time under Immune Selection
Angelova, M., Mlecnik, B., Vasaturo, A., Bindea, G., Fredriksen, T., Lafontaine, L., Buttard, B., Morgand, E., Bruni, D., Jouret-Mourin, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.018 · Cited by 457
Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131859 · Cited by 456
Single-cell analysis of human adipose tissue identifies depot- and disease-specific cell types
Vijay, J., Gauthier, M.-F., Biswell, R. L., Louiselle, D. A., Johnston, J. J., Cheung, W. A., Belden, B., Pramatarova, A., Biertho, L., Gibson, M., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0152-6 · Cited by 455
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454
Structural cells are key regulators of organ-specific immune responses
Krausgruber, T., Fortelny, N., Fife-Gernedl, V., Senekowitsch, M., Schuster, L. C., Lercher, A., Nemc, A., Schmidl, C., Rendeiro, A. F., Bergthaler, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2424-4 · Cited by 434
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Platten, M., Bunse, L., Wick, A., Bunse, T., Le Cornet, L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03363-z · Cited by 432
Toso, A., Revandkar, A., Di Mitri, D., Guccini, I., Proietti, M., Sarti, M., Pinton, S., Zhang, J., Kalathur, M., Civenni, G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.044 · Cited by 418
NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Ruscetti, M., Leibold, J., Bott, M. J., Fennell, M., Kulick, A., Salgado, N. R., Chen, C.-C., Ho, Y.-J., Sanchez-Rivera, F. J., Feucht, J., et al. (2018) · Science · doi:10.1126/science.aas9090 · Cited by 415
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
Ford, K., Hanley, C. J., Mellone, M., Szyndralewiez, C., Heitz, F., Wiesel, P., Wood, O., Machado, M., Lopez, M.-A., Ganesan, A.-P., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3158 · Cited by 411
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
Kohanbash, G., Carrera, D. A., Shrivastav, S., Ahn, B. J., Jahan, N., Mazor, T., Chheda, Z. S., Downey, K. M., Watchmaker, P. B., Beppler, C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90644 · Cited by 410
Mutant IDH1 regulates the tumor-associated immune system in gliomas
Amankulor, N. M., Kim, Y., Arora, S., Kargl, J., Szulzewsky, F., Hanke, M., Margineantu, D. H., Rao, A., Bolouri, H., Delrow, J., et al. (2017) · Genes & Development · doi:10.1101/gad.294991.116 · Cited by 405
Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion
Sun, X., Wu, B., Chiang, H.-C., Deng, H., Zhang, X., Xiong, W., Liu, J., Rozeboom, A. M., Harris, B. T., Blommaert, E., et al. (2021) · Nature · doi:10.1038/s41586-021-04057-2 · Cited by 401
Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas
Dongre, A., Rashidian, M., Reinhardt, F., Bagnato, A., Keckesova, Z., Ploegh, H. L., & Weinberg, R. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3292 · Cited by 395
Immune crosstalk in cancer progression and metastatic spread: a complex conversation
Garner, H., & de Visser, K. E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0271-z · Cited by 395
Self-citationSahin, I. H., Akce, M., Alese, O., Shaib, W., Lesinski, G. B., El-Rayes, B., & Wu, C. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0599-y · Cited by 393
Immune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387
Regulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 385
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 382
Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells
Santisteban, M., Reiman, J. M., Asiedu, M. K., Behrens, M. D., Nassar, A., Kalli, K. R., Haluska, P., Ingle, J. N., Hartmann, L. C., Manjili, M. H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3343 · Cited by 379
Stress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunity
Yang, H., Xia, L., Chen, J., Zhang, S., Martin, V., Li, Q., Lin, S., Chen, J., Calmette, J., Lu, M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0566-4 · Cited by 379
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Edwards, D. N., Ngwa, V. M., Raybuck, A. L., Wang, S., Hwang, Y., Kim, L. C., Cho, S. H., Paik, Y., Wang, Q., Zhang, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140100 · Cited by 377
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers
Hong, C., Schubert, M., Tijhuis, A. E., Requesens, M., Roorda, M., van den Brink, A., Ruiz, L. A., Bakker, P. L., van der Sluis, T., Pieters, W., et al. (2022) · Nature · doi:10.1038/s41586-022-04847-2 · Cited by 371
Adamstein, N. H., MacFadyen, J. G., Rose, L. M., Glynn, R. J., Dey, A. K., Libby, P., Tabas, I. A., Mehta, N. N., & Ridker, P. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1034 · Cited by 356
Xiao, Y., Ma, D., Zhao, S., Suo, C., Shi, J., Xue, M.-Z., Ruan, M., Wang, H., Zhao, J., Li, Q., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3524 · Cited by 352
Mutant p53 suppresses innate immune signaling to promote tumorigenesis
Ghosh, M., Saha, S., Bettke, J., Nagar, R., Parrales, A., Iwakuma, T., van der Velden, A. W. M., & Martinez, L. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.003 · Cited by 348
Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 340
p53, cancer and the immune response
Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333
Zhang, X., Shi, H., Yuan, X., Jiang, P., Qian, H., & Xu, W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0898-6 · Cited by 332
Guidoboni, M., Gafà, R., Viel, A., Doglioni, C., Russo, A., Santini, A., Del Tin, L., Macrì, E., Lanza, G., Boiocchi, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61695-1 · Cited by 322
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis
Li, J., Duran, M. A., Dhanota, N., Chatila, W. K., Bettigole, S. E., Kwon, J., Sriram, R. K., Humphries, M. P., Salto-Tellez, M., James, J. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0387 · Cited by 312
Ye, L., Zhang, Q., Cheng, Y., Chen, X., Wang, G., Shi, M., Zhang, T., Cao, Y., Pan, H., Zhang, L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0451-6 · Cited by 293
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy
Saleh, T., Bloukh, S., Carpenter, V. J., Alwohoush, E., Bakeer, J., Darwish, S., Azab, B., & Gewirtz, D. A. (2020) · Cancers · doi:10.3390/cancers12040822 · Cited by 290
Sugiyama, E., Togashi, Y., Takeuchi, Y., Shinya, S., Tada, Y., Kataoka, K., Tane, K., Sato, E., Ishii, G., Goto, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3937 · Cited by 289
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Chen, N., Fang, W., Lin, Z., Peng, P., Wang, J., Zhan, J., Hong, S., Huang, J., Liu, L., Sheng, J., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2005-z · Cited by 288
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285
SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion
Kitamura, T., Kometani, K., Hashida, H., Matsunaga, A., Miyoshi, H., Hosogi, H., Aoki, M., Oshima, M., Hattori, M., Takabayashi, A., et al. (2007) · Nature Genetics · doi:10.1038/ng1997 · Cited by 285
Liu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.027 · Cited by 281
Lehmann, B. D., Colaprico, A., Silva, T. C., Chen, J., An, H., Ban, Y., Huang, H., Wang, L., James, J. L., Balko, J. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26502-6 · Cited by 279
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B. C., Jia, L., Gartner, J. J., Hill, V., Yu, Z., Restifo, N. P., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123791 · Cited by 275
Wu, S., Zhang, Q., Zhang, F., Meng, F., Liu, S., Zhou, R., Wu, Q., Li, X., Shen, L., Huang, J., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0352-z · Cited by 275
Mehta, A. K., Cheney, E. M., Hartl, C. A., Pantelidou, C., Oliwa, M., Castrillon, J. A., Lin, J.-R., Hurst, K. E., de Oliveira Taveira, M., Johnson, N. T., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00148-7 · Cited by 275
Song, M., Chen, D., Lu, B., Wang, C., Zhang, J., Huang, L., Wang, X., Timmons, C. L., Hu, J., Liu, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065821 · Cited by 266
Correlation of immune phenotype with IDH mutation in diffuse glioma
Berghoff, A. S., Kiesel, B., Widhalm, G., Wilhelm, D., Rajky, O., Kurscheid, S., Kresl, P., Wöhrer, A., Marosi, C., Hegi, M. E., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox054 · Cited by 254
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer
Maeda, T., Hiraki, M., Jin, C., Rajabi, H., Tagde, A., Alam, M., Bouillez, A., Hu, X., Suzuki, Y., Miyo, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1636 · Cited by 250
Androgen conspires with the CD8 + T cell exhaustion program and contributes to sex bias in cancer
Kwon, H., Schafer, J. M., Song, N.-J., Kaneko, S., Li, A., Xiao, T., Ma, A., Allen, C., Das, K., Zhou, L., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq2630 · Cited by 244
Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy
Xu, Y.-P., Lv, L., Liu, Y., Smith, M. D., Li, W.-C., Tan, X.-M., Cheng, M., Li, Z., Bovino, M., Aubé, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129317 · Cited by 228
Mgrditchian, T., Arakelian, T., Paggetti, J., Noman, M. Z., Viry, E., Moussay, E., Van Moer, K., Kreis, S., Guerin, C., Buart, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703921114 · Cited by 226
Caetano, M. S., Zhang, H., Cumpian, A. M., Gong, L., Unver, N., Ostrin, E. J., Daliri, S., Chang, S. H., Ochoa, C. E., Hanash, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2840 · Cited by 225
Ying, H., Elpek, K. G., Vinjamoori, A., Zimmerman, S. M., Chu, G. C., Yan, H., Fletcher-Sananikone, E., Zhang, H., Liu, Y., Wang, W., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0031 · Cited by 223
Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation
Welte, T., Kim, I. S., Tian, L., Gao, X., Wang, H., Li, J., Holdman, X. B., Herschkowitz, J. I., Pond, A., Xie, G., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3355 · Cited by 216
Yang, L., Li, A., Lei, Q., & Zhang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0804-8 · Cited by 215
Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer
Bagati, A., Kumar, S., Jiang, P., Pyrdol, J., Zou, A. E., Godicelj, A., Mathewson, N. D., Cartwright, A. N. R., Cejas, P., Brown, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.001 · Cited by 215
Emerging role of PTEN loss in evasion of the immune response to tumours
Vidotto, T., Melo, C. M., Castelli, E., Koti, M., dos Reis, R. B., & Squire, J. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0834-6 · Cited by 209
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 205
The Role of Autophagy in Cancer
Santana-Codina, N., Mancias, J. D., & Kimmelman, A. C. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041816-122338 · Cited by 201
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1β
Shchors, K., Shchors, E., Rostker, F., Lawlor, E. R., Brown-Swigart, L., & Evan, G. I. (2006) · Genes & Development · doi:10.1101/gad.1455706 · Cited by 200
Asgarova, A., Asgarov, K., Godet, Y., Peixoto, P., Nadaradjane, A., Boyer-Guittaut, M., Galaine, J., Guenat, D., Mougey, V., Perrard, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423170 · Cited by 199
The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
Ma, J., Setton, J., Lee, N. Y., Riaz, N., & Powell, S. N. (2018) · Nature Communications · doi:10.1038/s41467-018-05228-y · Cited by 195
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
Metadata
- Authors
- van Weverwijk, A., & de Visser, K. E.
- Venue
- Nature Reviews Cancer
- Published
- 2023-01-30
- Volume
- 23
- Issue
- 4
- Pages
- 193-215
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W4318483748
- Cited by
- 272
- References
- 311
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.